Literature DB >> 1636590

New developments in pharmacologic stress imaging.

F P van Rugge1, E E van der Wall, A V Bruschke.   

Abstract

The clinical usefulness of cardiac imaging modalities that rely upon the detection of perfusion defects and wall motion disturbances requires conditions that provoke a heterogeneity of coronary flow and a myocardial oxygen imbalance, respectively. Traditionally, this has been achieved by exercise stress testing. Many patients cannot perform dynamic exercise sufficiently for various reasons. Pharmacologic stress has been proven to be an attractive alternative for physical exercise. Currently, several stressing agents are used in conjunction with thallium-201 scintigraphy, 2-D echocardiography and, recently, MRI. The most employed agents include vasodilators, such as dipyridamole and adenosine, and catecholamines, such as dobutamine (Table VI). The predominant rationale of thallium-201 perfusion scintigraphy is based on the creation of a flow maldistribution between territories supplied by normal arteries and those supplied by stenotic arteries that does not necessarily require ischemia. Dipyridamole and adenosine, as rather selective coronary vasodilators, are well suited to provoke such a condition and may be classified as the ideal markers of myocardial perfusion. 2-D echocardiography and MRI have the potential to provide noninvasively derived information of cardiac dynamics and regional myocardial function. To assess the functional significance of coronary artery disease, detection of wall motion abnormalities and alterations in ejection fraction require the presence of myocardial ischemia. Dobutamine, as a widely applied inotropic agent in the management of severely depressed left ventricular contractile function, seems to be an appropriate pharmacologic stressor when heart failure is absent. By increasing contractility, heart rate, and systolic arterial pressure, it is capable of inducing an imbalance between myocardial oxygen demand and supply, leading to ischemia in patients with coronary artery disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1636590     DOI: 10.1016/0002-8703(92)90614-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  16 in total

1.  Signal intensity enhances diagnostic capacity in myocardial infarction.

Authors:  A van der Laarse; E E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2009-03-17       Impact factor: 2.357

2.  Duchenne muscular dystrophy; a cardiomyopathy that can be prevented?

Authors:  Barbara J M Mulder; Ernst E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2008-10-01       Impact factor: 2.357

Review 3.  A consideration of current clinical options for stress imaging in the diagnosis and evaluation of coronary artery disease.

Authors:  E H Botvinick
Journal:  J Nucl Cardiol       Date:  1994 Sep-Oct       Impact factor: 5.952

4.  Echocardiography in Takotsubo cardiomyopathy; a useful approach?

Authors:  E E van der Wall; E R Holman; A J Scholte; J J Bax
Journal:  Int J Cardiovasc Imaging       Date:  2010-06       Impact factor: 2.357

5.  Tissue characterization in Takotsubo cardiomyopathy; a valuable approach?

Authors:  E E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2010-02       Impact factor: 2.357

6.  Cardiac magnetic resonance imaging analysis in STEMI: quantitative or still visual?

Authors:  E E van der Wall; J J Bax; J H Reiber
Journal:  Int J Cardiovasc Imaging       Date:  2010-05-08       Impact factor: 2.357

7.  Assessment of left ventricular function: visual or quantitative?

Authors:  E E van der Wall; J H C Reiber
Journal:  Int J Cardiovasc Imaging       Date:  2010-10-28       Impact factor: 2.357

8.  Speckle tracking: distinction of physiologic from pathologic LVH?

Authors:  E E van der Wall; V Delgado; E R Holman; J J Bax
Journal:  Int J Cardiovasc Imaging       Date:  2010-08-24       Impact factor: 2.357

9.  Cardiac magnetic resonance imaging in primary PCI: additional value?

Authors:  E E van der Wall; J J Bax; J W Jukema; M J Schalij
Journal:  Int J Cardiovasc Imaging       Date:  2009-05-26       Impact factor: 2.357

10.  Cardiovascular dynamics in ischemic cardiomyopathy during exercise.

Authors:  E E van der Wall; J J Bax; C A Swenne; P Steendijk; M J Schalij
Journal:  Int J Cardiovasc Imaging       Date:  2010-02       Impact factor: 2.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.